Drugs / MUFEMILAST

Trials 17 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 19 trials
Phase 1 NCT06610890 Dec 2024 → Jan 2025 psoriasis Ganzhou Hemay Pharmaceutical Co., Ltd Completed No outcome recorded
Phase 1 NCT06380153 May 2024 → Apr 2025 psoriasis Ganzhou Hemay Pharmaceutical Co., Ltd Completed No outcome recorded
Phase 1 NCT06376474 Apr 2024 → Dec 2025 overdue psoriasis Ganzhou Hemay Pharmaceutical Co., Ltd Recruiting No outcome recorded
Phase 1 NCT05941247 Jul → Aug 2023 Ganzhou Hemay Pharmaceutical Co., Ltd Completed No outcome recorded
Phase 1 NCT05468645 Jul → Sep 2022 Ganzhou Hemay Pharmaceutical Co., Ltd Completed No outcome recorded
Phase 1 NCT04837235 Apr → Aug 2021 psoriasis Tianjin Hemay Pharmaceutical Co., Ltd Completed No outcome recorded
Phase 1 NCT03577626 Oct → Nov 2018 psoriasis Tianjin Hemay Bio-Tech Co., Ltd Unknown No outcome recorded
Phase 1 NCT03570346 Jul → Oct 2018 psoriasis Tianjin Hemay Bio-Tech Co., Ltd Unknown No outcome recorded
Phase 1 NCT03007810 Dec 2016 → Jun 2018 psoriasis Tianjin Hemay Bio-Tech Co., Ltd Completed No outcome recorded
Phase 25 trials
Phase 2 NCT07314242 Jan 2026 → Dec 2027 expected chronic obstructive pulmonary disease Ganzhou Hemay Pharmaceutical Co., Ltd Not yet recruiting No outcome recorded
Phase 2 NCT05769946 Nov 2022 → Jan 2024 atopic eczema Ganzhou Hemay Pharmaceutical Co., Ltd Completed No outcome recorded
Phase 2 NCT05486104 Nov 2022 → Dec 2026 expected ulcerative colitis Ganzhou Hemay Pharmaceutical Co., Ltd Active not recruiting No outcome recorded
Phase 2 NCT04609397 Nov 2020 → Apr 2022 Behcet disease Tianjin Hemay Pharmaceutical Co., Ltd Terminated No outcome recorded
Phase 2 NCT04102241 May 2019 → Oct 2020 psoriasis Tianjin Hemay Pharmaceutical Co., Ltd Completed No outcome recorded
Phase 33 trials
Phase 3 NCT07650942 Jun 2026 → May 2028 expected ulcerative colitis Ganzhou Hemay Pharmaceutical Co., Ltd Not yet recruiting No outcome recorded
Phase 3 NCT06145893 Nov 2023 → May 2026 overdue Behcet disease Ganzhou Hemay Pharmaceutical Co., Ltd Recruiting No outcome recorded
Phase 3 NCT04839328 Jan → Oct 2022 psoriasis Tianjin Hemay Pharmaceutical Co., Ltd Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT06908642 Comparator Dec 2024 → Jun 2025 chronic obstructive pulmonary disease Anhui Hemay Pharmaceutical Co., Ltd Completed No outcome recorded
Phase 21 trial
Phase 2 NCT05407246 Comparator Aug 2022 → Aug 2023 ankylosing spondylitis Tianjin Hemay Pharmaceutical Co., Ltd Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 20 sources stand behind the page.

FieldValueCited text
Known as MUFEMILAST ChEMBL registry synonym — accepted as the source's own label CHEMBL5095240
Known as [14C]Hemay005 “In Vivo Mass Balance Study of [14C]Hemay005NCT05468645
Known as Hemay005 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05486104
18

NCT06145893

NCT03007810

NCT05769946

NCT04839328

NCT06908642

NCT05941247

NCT06610890

NCT07314242

NCT04837235

NCT03570346

NCT06380153

NCT04102241

NCT05407246

NCT07650942

NCT05468645

NCT04609397

NCT06376474

NCT03577626

Known as Hemay005 tablet Hemay005 tabletNCT04839328
Action Inhibit “Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis.” NCT03570346
Modality Small molecule “Hemay005 is a small molecule PDE4 inhibitor.” NCT04102241
Route Oral “Subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg) orally single dose” NCT03007810